AbbVie Inc Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 353 trades in AbbVie Inc (NYSE: ABBV) since 2013, across 55 members, worth an estimated $6M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 193 buys against 159 sells, a modestly buy-led skew, with Democratic members responsible for 61% of the trades and Republican members 39%. The most recent disclosure shown was filed June 2026, and Lisa Mcclain has filed the most ABBV transactions among those shown, with 12. Other recent filers include Josh Gottheimer, Ro Khanna, and Julie Johnson. One notable disclosed move was a purchase by Lisa Mcclain on June 17, 2025, up 26.8% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the AbbVie Inc (ABBV) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
AbbVie congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | |
|---|---|---|---|---|---|---|---|
 Josh Gottheimer House | Jun 3, 2026 | May 5, 2026 | 29 days | SELL |  $1,001 - $15,000 | +10.49% | |
 Ro Khanna House | Apr 7, 2026 | Mar 30, 2026 | 8 days | SELL | $15,001 - $50,000 | +7.74% | |
Ro Khanna House | Mar 9, 2026 | Feb 5, 2026 | 32 days | BUY | $15,001 - $50,000 | +4.84% | |
Ro Khanna House | Feb 6, 2026 | Jan 29, 2026 | 8 days | SELL | $15,001 - $50,000 | +4.17% | |
Ro Khanna House | Feb 6, 2026 | Jan 23, 2026 | 14 days | BUY | $1,001 - $15,000 | +4.72% | |
 Julie Johnson House | Jan 16, 2026 | Dec 18, 2025 | 29 days | SELL | $1,001 - $15,000 | +3.88% | |
Julie Johnson House | Jan 15, 2026 | Dec 18, 2025 | 28 days | SELL | $1,001 - $15,000 | +3.88% | |
 Julia Letlow House | Jan 14, 2026 | Dec 8, 2025 | 37 days | SELL | $1,001 - $15,000 | +3.74% | |
Julia Letlow House | Jan 13, 2026 | Dec 8, 2025 | 36 days | SELL | $1,001 - $15,000 | +3.74% | |
Julie Johnson House | Dec 12, 2025 | Nov 13, 2025 | 29 days | SELL | $1,001 - $15,000 | -0.35% |
AbbVie (ABBV) congressional trading FAQ
Can members of Congress legally trade AbbVie (ABBV) stock?
Yes. Members of Congress are permitted to trade individual stocks, including AbbVie (ABBV), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; it does not imply any trade was improper.
Are congressional AbbVie (ABBV) trades public?
Yes. Every congressional trade in AbbVie (ABBV) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded AbbVie (ABBV)?
Members of Congress have disclosed 353 trades in AbbVie (ABBV) worth $6M across 55 members, according to public STOCK Act filings.
Which members of Congress have traded AbbVie (ABBV)?
Recent and active filers of AbbVie (ABBV) disclosures include Lisa Mcclain, Ro Khanna, Julie Johnson. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade AbbVie (ABBV) more?
Across disclosed AbbVie (ABBV) trades, 61% were by Democrats and 39% by Republicans, led by Democrats (61%).
What is the most recent congressional AbbVie (ABBV) trade?
The most recent disclosed AbbVie (ABBV) trade was a sale by Josh Gottheimer, filed Jun 2, 2026.
Browse all stocks Congress tradesCongressional trading overviewAbbVie (ABBV) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.